Much has been made of the potential of continuous platforms to supplant traditional pharmaceutical batch manufacturing and drive down API production costs. But how suitable is the technology to the precise requirements of complex pharma processing?
Biotech accuses VGXI of blocking roll-out by refusing to facilitate tech transfer to third-party manufacturers
The rush to find effective vaccines against the coronavirus is only one part of the story. How is the pharmaceutical industry addressing the difficult issue of ensuring there will be enough manufacturing capacity to roll them out on a global scale?
Development partners believe orthopoxvirus vaccines have potential for scalability to supply very large markets